PureTech launch­es an I/O start­up in­spired by NYU’s George Miller; SV adopts a new name

→ PureTech is launch­ing a new biotech, this time fo­cus­ing on the im­muno-on­col­o­gy work done by NYU’s George Miller. It’s named Ny­bo Ther­a­peu­tics, and like a lot of PureTech up­starts, the an­nounce­ment is long on rep­u­ta­tions/names and short on terms, for now. “Most sol­id, ma­lig­nant tu­mors es­tab­lish an im­muno­sup­pres­sive en­vi­ron­ment to ward off the body’s nat­ur­al de­fens­es. Dr. Miller’s work in pan­cre­at­ic duc­tal car­ci­no­ma has re­vealed that in­flam­ma­to­ry process­es dri­ve the im­muno­sup­pres­sion through cer­tain gam­ma delta T cells and macrophages,” said Joseph Bolen, Chief Sci­en­tif­ic Of­fi­cer of PureTech Health. “Our nov­el ap­proach builds on this find­ing and se­lec­tive­ly dis­rupts the im­muno­sup­pres­sion to po­ten­tial­ly have a ther­a­peu­tic ef­fect on can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER